Publication:
Prognostic value of preoperative De Ritis ratio on oncological outcomes in patients with muscle-invasive bladder cancer

dc.contributor.authorSretenovic, Milan (57222981469)
dc.contributor.authorLisicic, Nikola (58288887800)
dc.contributor.authorBulat, Petar (59060084900)
dc.contributor.authorRadisavcevic, Djordje (57222992997)
dc.contributor.authorBumbasirevic, Uros (36990205400)
dc.contributor.authorCegar, Bojan (55376116500)
dc.contributor.authorMilojevic, Isidora Grozdic (37107616900)
dc.contributor.authorGrujicic, Sandra Sipetic (56676073300)
dc.contributor.authorMilojevic, Bogomir (36990126400)
dc.date.accessioned2025-06-12T11:48:16Z
dc.date.available2025-06-12T11:48:16Z
dc.date.issued2024
dc.description.abstractObjective: We aimed to assess the prognostic value of De Ritis ratio on oncological outcomes in patients suffering from urothelial bladder cancer and undergoing radical cystectomy (RC). Patients and Methods: Analytical cohort comprised a single-center series of 367 patients treated between January 2015 and December 2018. Patients were classified into two groups based on De Ritis ratio (<1.3 [normal] vs. ≥1.3 [high]). Along with the Kaplan-Meier survival probability, cox proportional hazard regression models were used. Results: A total of 299 patients were included, 60.5% of them having a De Ritis ratio of <1.3% and 39.5% with a De Ritis ratio of ≥1.3. Preoperative increased De Ritis ratio was associated with age (p = 0.001), gender (p = 0.044), cancer-related death (p = 0.001), overall death (p = 0.001), and tumor stage (p = 0.001). Multivariate analysis implied that preoperative De Ritis ratio was a significant independent prognosticator of overall survival (HR 0.461; 95% CI 0.335–0.633; p < 0.001) and CSS (HR 0.454; 95% CI 0.330–0.623; p < 0.001). Only tumor stage (HR 1.953; 95% CI 1. 106–3.448; p = 0.021) was independently associated with recurrence-free survival (RFS). De Ritis ratio was not independently associated with RFS in multivariate analyses. During the follow up, a total of 198 (66.2%) patients died, including 173 (57.9%) from BC, 5-year CSS was 45.8%. Conclusions: De Ritis ratio is an independent prognostic factor of cancer specific and overall survival in patients treated with RC for urothelial BC. RC patients may benefit from the use of the De Ritis ratio as a valid predictive biomarker. © 2023 Wiley Periodicals LLC.
dc.identifier.urihttps://doi.org/10.1002/jso.27517
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85176952233&doi=10.1002%2fjso.27517&partnerID=40&md5=6a93bec82947f8d0f2e3258be6a1188e
dc.identifier.urihttps://remedy.med.bg.ac.rs/handle/123456789/1283
dc.subjectDe Ritis ratio
dc.subjectradical cystectomy
dc.subjectsurvival
dc.subjecturothelial bladder cancer
dc.titlePrognostic value of preoperative De Ritis ratio on oncological outcomes in patients with muscle-invasive bladder cancer
dspace.entity.typePublication

Files